Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Disease

December 19, 2019

View Press Release Corporate presentation Contact us
Previous